List of Excipients in Branded Drug UDENYCA

Udenyca Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Udenyca, pegfilgrastim-cbq, uses a conventional low-complexity excipient system designed to preserve protein stability while supporting a 6 mg subcutaneous dose in a 0.6 mL volume. Its commercial differentiation comes less from novel excipients than from device-enabled administration, biosimilar economics, supply reliability, and potential lifecycle extensions.

The core formulation contains sodium acetate, sorbitol, polysorbate 20, and water for injection. Udenyca is FDA-approved as a biosimilar to Neulasta and is available through a prefilled syringe and the UDENYCA Onbody wearable injector. The Onbody presentation creates the strongest commercial opportunity because it addresses the clinical and operational burden of next-day post-chemotherapy administration.[1,2]

What excipients are used in Udenyca?

Udenyca’s formulation contains four inactive ingredients:

Component	Reported amount per 0.6 mL	Primary formulation role
Sorbitol	30 mg	Tonicity adjustment and protein-stabilizing polyol
Sodium acetate	0.35 mg	Buffering and pH control
Polysorbate 20	0.02 mg	Suppression of surface adsorption and aggregation
Water for injection	q.s. to 0.6 mL	Injectable vehicle

The product is supplied as pegfilgrastim-cbq at 6 mg per 0.6 mL, with a formulation pH of approximately 4.0.[1]

How does sorbitol support pegfilgrastim stability?

Sorbitol is a nonreducing polyol used to support protein structure and adjust osmolality. For a subcutaneous biologic administered in a small volume, sorbitol can provide tonicity without introducing the reducing chemistry associated with some sugars.

Its commercial value is practical rather than proprietary. Sorbitol is widely available, inexpensive, and familiar to regulators. It does not materially raise manufacturing complexity, but its concentration must be controlled because excessive osmolality can increase injection-site discomfort.

Why is polysorbate 20 included?

Polysorbate 20 reduces adsorption of pegfilgrastim to vial, syringe, cartridge, and device surfaces. It also helps limit interfacial aggregation caused by agitation during shipping, handling, and administration.

Polysorbate degradation is a known biologic-development concern. Hydrolysis can generate free fatty acids, while oxidation can create reactive species that affect protein quality. For Udenyca, the low polysorbate concentration reduces excipient burden but places greater importance on control of raw-material quality, oxygen exposure, light, agitation, and storage conditions.

The main development opportunity is not simply substituting another surfactant. A replacement would require comparative characterization, stability studies, container-closure evaluation, and potentially a regulatory supplement or new product development program.

What is the role of sodium acetate?

Sodium acetate provides buffering near the product’s acidic formulation pH. Buffer selection affects protein charge, aggregation, chemical degradation, syringe compatibility, and injection tolerability.

Acetate is a commercially accessible buffer with an established parenteral-use history. Its use supports a relatively simple formulation strategy and avoids dependence on higher-cost proprietary excipient systems.

What formulation patents protect Udenyca?

Udenyca’s principal regulatory protection is based on biologic approval, manufacturing know-how, analytical comparability, and device integration rather than a publicly apparent novel excipient platform.

Because Udenyca is a biosimilar, the FDA does not treat its formulation as a generic small-molecule formulation under an ANDA. Udenyca was approved under the 351(k) biosimilar pathway, and its regulatory record is maintained through the Purple Book rather than the Orange Book.[2,3]

What is the Orange Book status of Udenyca?

Udenyca does not have a conventional Orange Book listing because it is a biologic approved under a BLA pathway. The relevant regulatory records are:

Issue	Udenyca status
Active ingredient	Pegfilgrastim-cbq
Reference product	Neulasta, pegfilgrastim
FDA pathway	Section 351(k) biosimilar
Reference BLA	Neulasta BLA 125031
Orange Book listing	Not the principal listing mechanism
Purple Book relevance	Yes
Product-level patent disputes	Generally handled through the Biologics Price Competition and Innovation Act framework

The absence of an Orange Book listing does not eliminate patent risk. Patent disputes can involve manufacturing processes, protein sequences, formulations, delivery devices, injection systems, and methods of use.

Are Udenyca excipients independently patentable?

Individual excipients such as sorbitol, sodium acetate, and polysorbate 20 generally offer limited exclusivity because they are established pharmaceutical materials. Commercially meaningful patent positions would more likely cover:

• Narrow concentration ranges that improve pegfilgrastim stability.
• Reduced aggregation or oxidation during storage.
• Compatibility with a wearable injector or cartridge.
• Low-volume administration systems.
• Long-term refrigerated stability.
• Freeze-thaw or shipping robustness.
• Manufacturing methods that reduce host-cell protein, aggregates, or process-related impurities.
• Device-formulation combinations.

A formulation patent would need a defensible technical effect over known pegfilgrastim formulations. Simply combining pegfilgrastim with conventional excipients would face substantial obviousness and written-description challenges.

When did Udenyca obtain FDA approval and exclusivity?

The FDA approved Udenyca on November 2, 2018, as a biosimilar to Neulasta.[2] Coherus launched the product in the United States in January 2020 after resolving patent-related barriers with Amgen.[4]

Udenyca did not receive the first interchangeable designation for pegfilgrastim. Its commercial position has therefore depended on biosimilar approval, contracting, pricing, supply, and administration convenience rather than automatic pharmacy substitution.

What exclusivity does Udenyca have?

Udenyca has no standalone 12-year reference-product exclusivity period. That period applies to the reference biologic, not to a biosimilar. A biosimilar’s commercial protection instead depends on:

• The reference product’s biologic exclusivity period.
• Patent settlements and launch dates.
• Manufacturing and regulatory barriers.
• Contracting and channel access.
• Device differentiation.
• Any product-specific patent rights.

The reference product Neulasta was approved in 2002, making Udenyca part of a mature biologic competition cycle rather than an early exclusivity market.[5]

How does Udenyca’s excipient strategy compare with competing pegfilgrastim products?

The major competing pegfilgrastim products include Ziextenzo, Fulphila, Nyvepria, Stimufend, and other FDA-approved biosimilars or follow-on products. Product-by-product excipient differences can affect stability, device compatibility, injection experience, and manufacturing cost.

Product	Sponsor or manufacturer	Product type	Commercial differentiation
Udenyca	Coherus BioSciences	Pegfilgrastim biosimilar	Prefilled syringe and Onbody delivery
Neulasta	Amgen	Reference product	Established clinical and payer position
Ziextenzo	Sandoz	Pegfilgrastim biosimilar	Global commercial infrastructure
Fulphila	Viatris	Pegfilgrastim biosimilar	Broad biosimilar portfolio and contracting
Nyvepria	Pfizer	Pegfilgrastim biosimilar	Large institutional and hospital presence
Stimufend	Fresenius Kabi	Pegfilgrastim biosimilar	Oncology-focused commercial platform

The relevant comparison is not whether one product uses sorbitol and another uses a different polyol. The higher-value questions are whether the formulation supports:

1. Stable shelf life through distribution.
2. Low particulate and aggregate levels.
3. Reliable delivery through an autoinjector or wearable injector.
4. Acceptable injection-site tolerability.
5. Consistent supply at biosimilar pricing.

Public labels should be used for the current inactive-ingredient composition of each competitor because formulations and presentations can vary by device and market.[1,6-9]

What formulations are protected by Udenyca’s product strategy?

The highest-value formulation opportunity is the combination of pegfilgrastim with a delivery system that permits administration after chemotherapy without a return visit.

Udenyca prefilled syringe

The prefilled syringe is the simpler presentation. It has lower device complexity, established manufacturing infrastructure, and broad use in clinics and specialty pharmacies. The formulation must withstand:

• Silicone oil or other syringe-contact materials.
• Extractables and leachables.
• Mechanical agitation.
• Cold-chain distribution.
• Manual injection by a healthcare professional or caregiver.

This presentation is suited to cost-sensitive contracting and institutions with established injection workflows.

UDENYCA Onbody

The UDENYCA Onbody system is a wearable injector intended to deliver pegfilgrastim after chemotherapy. The product was FDA-approved in 2022.[10]

The Onbody presentation expands the formulation design space. The product must remain stable in a cartridge or wearable reservoir and deliver the intended dose through a programmed injection sequence. Relevant technical requirements include:

• Device-reservoir compatibility.
• Flow through the delivery needle or cannula.
• Adhesive and skin-contact compatibility.
• Protection against accidental activation.
• Resistance to vibration and temperature excursions.
• Dose accuracy over the delivery period.
• Low particle formation during device operation.

The excipient system therefore becomes part of a device-platform strategy. A formulation that performs adequately in a conventional syringe may not perform identically in a wearable injector.

What commercial opportunities exist for Udenyca excipient and formulation technology?

Wearable oncology delivery

The strongest opportunity is expansion of wearable delivery beyond the current pegfilgrastim product. A stable low-volume biologic formulation compatible with an on-body injector can support additional oncology products requiring delayed or timed administration.

Potential targets include colony-stimulating factors, supportive-care biologics, and selected oncology agents where post-infusion administration is clinically established.

Contract manufacturing and device partnerships

Companies with expertise in low-volume biologics, cartridge filling, wearable injectors, or combination-product assembly can pursue partnerships with biosimilar sponsors. The most defensible value lies in integrated development capability, not in supplying commodity sorbitol or polysorbate 20.

Potential partnership assets include:

• Dual-chamber or cartridge-based delivery systems.
• Prefilled wearable systems.
• Low-shear filling and assembly.
• Real-time particulate monitoring.
• Device-specific stability packages.
• Global combination-product regulatory support.

Excipient substitution and surfactant innovation

A replacement for polysorbate 20 could have value if it materially reduces oxidation, hydrolysis, visible particles, or protein aggregation. Candidate technologies include more oxidation-resistant surfactants, protein-compatible amphiphiles, and low-peroxide excipient grades.

The commercial hurdle is high. Any new excipient must demonstrate a clear product benefit, supply security, toxicology acceptability, and regulatory support. For a mature biosimilar with pricing pressure, the cost and approval burden may outweigh the benefit unless the new formulation enables a meaningful device or shelf-life advantage.

Regional and global formulation localization

Udenyca’s commercial opportunity differs by jurisdiction. In the United States, payer contracting and site-of-care economics dominate. In Europe, hospital tenders and national reimbursement decisions carry greater weight. In emerging markets, room-temperature stability, reduced cold-chain dependence, and local fill-finish capability can be more valuable than a premium wearable device.

A formulation with improved excursion stability could support distribution in markets where refrigerated logistics are less reliable. That opportunity would require validated stability data and local regulatory acceptance.

Which companies are challenging Udenyca commercially?

Udenyca faces competition from the reference product Neulasta and multiple pegfilgrastim biosimilars. The competitive landscape is shaped by:

• Net price and rebate strategy.
• Payer and group-purchasing contracts.
• Hospital formulary placement.
• Availability of prefilled syringes.
• Availability of on-body delivery.
• Manufacturing reliability.
• Regulatory interchangeability status.
• Physician and patient familiarity.

Large companies such as Amgen, Sandoz, Viatris, Pfizer, and Fresenius Kabi have broader commercial infrastructure. Coherus has a more concentrated oncology and biosimilar strategy, making Udenyca’s device differentiation and supply execution especially important.[4,6-9]

What patent litigation and settlement issues affect Udenyca?

Udenyca entered the market after patent litigation and settlement activity involving Amgen’s Neulasta estate. The commercial launch timing reflected resolution of patent barriers rather than the expiration of every potentially relevant patent claim.[4]

For future Udenyca extensions, risk areas include:

• New wearable-injector patents.
• Cartridge and reservoir patents.
• Needle and cannula systems.
• Formulation-device combination claims.
• Manufacturing patents for pegfilgrastim.
• Method-of-use claims for chemotherapy-induced neutropenia.
• Patent thickets surrounding reference-product delivery systems.

Settlement agreements can establish launch dates, geographic rights, authorized-generic arrangements, or restrictions on particular presentations. Public company filings and court records should be reviewed for any later amendments affecting Udenyca or the Onbody product.

How strong is the Udenyca patent estate?

The excipient estate alone is likely moderate to weak because the named excipients are conventional. The stronger protection is likely to arise from the combined product architecture:

1. Pegfilgrastim-cbq production and purification.
2. Analytical methods supporting biosimilar comparability.
3. Syringe or cartridge compatibility.
4. Wearable injector design.
5. Device control software and delivery sequence.
6. Product-specific manufacturing controls.
7. Combination-product stability.

This type of protection is difficult to design around if the commercial product depends on the same delivery workflow. It is easier to design around when the competitor can use a conventional prefilled syringe and accept a less differentiated administration model.

What generic or biosimilar entry risks exist?

Traditional generic entry risk does not apply in the same manner as it does for a small molecule. The main risk is additional biosimilar entry, followed by price erosion and payer-driven substitution.

A new competitor could enter through:

• A prefilled syringe with a lower net price.
• An interchangeable biosimilar designation.
• A differentiated on-body injector.
• A regional supply agreement.
• A hospital tender strategy.
• A formulation with extended temperature stability.

The greatest pressure would arise from a competitor combining interchangeability, reliable supply, and an equivalent or superior wearable presentation.

Key Takeaways

• Udenyca uses a conventional formulation containing sorbitol, sodium acetate, polysorbate 20, and water for injection.
• The excipient system is optimized for protein stability, tonicity, and subcutaneous administration rather than composition-of-matter exclusivity.
• UDENYCA Onbody is the main formulation-device commercial differentiator.
• Udenyca is regulated as a 351(k) biosimilar and is tracked through the Purple Book, not primarily through the Orange Book.
• The strongest IP opportunities involve device integration, cartridge compatibility, manufacturing, and formulation-device combinations.
• Commercial growth depends on payer access, hospital contracting, supply reliability, and reducing post-chemotherapy administration burden.
• Biosimilar competition is the principal long-term pricing risk.
• New excipient technology has commercial value only if it improves stability, device performance, shelf life, or distribution economics enough to justify regulatory redevelopment.

FAQs

Can Udenyca’s sorbitol formulation be used in another pegfilgrastim biosimilar?

Possibly, but a competitor would need to establish its own formulation, process, stability, device compatibility, and biosimilarity package. The presence of sorbitol alone is unlikely to create meaningful exclusivity.

Does UDENYCA Onbody require a different formulation from the prefilled syringe?

The presentations use the same active biologic and a closely related formulation strategy, but the wearable system imposes additional requirements for reservoir compatibility, dose delivery, mechanical stress, and container-closure performance.

Can a new surfactant create a patentable Udenyca lifecycle product?

Yes, if the surfactant produces an unexpected and measurable benefit, such as lower aggregation, better device stability, longer shelf life, or improved temperature-excursion performance. A routine polysorbate substitution would face a weaker patent position.

Is Udenyca interchangeable with Neulasta?

FDA biosimilar approval does not automatically establish interchangeability. Pharmacy-level substitution depends on the product’s FDA designation, state law, payer policy, and institutional purchasing rules.

What is the most valuable commercial extension for Udenyca?

The most valuable extension is a delivery platform that reduces clinic visits while maintaining low manufacturing cost and reliable dose delivery. The Onbody system provides the clearest existing pathway, while improved temperature stability and broader combination-product use offer longer-term opportunities.

References

1. U.S. Food and Drug Administration. (2024). Udenyca (pegfilgrastim-cbq) prescribing information. Coherus BioSciences, Inc.

2. U.S. Food and Drug Administration. (2018, November 2). FDA approves first biosimilar to pegfilgrastim to help reduce the chance of infection during cancer treatment. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

4. Coherus BioSciences, Inc. (2020). Annual report on Form 10-K for the year ended December 31, 2019. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2002). Neulasta approval history and prescribing information. https://www.accessdata.fda.gov

6. U.S. Food and Drug Administration. (2024). Ziextenzo (pegfilgrastim-bmez) prescribing information. Sandoz Inc.

7. U.S. Food and Drug Administration. (2024). Fulphila (pegfilgrastim-jmdb) prescribing information. Viatris Specialty LLC.

8. U.S. Food and Drug Administration. (2024). Nyvepria (pegfilgrastim-apgf) prescribing information. Pfizer Inc.

9. U.S. Food and Drug Administration. (2024). Stimufend (pegfilgrastim-fpgk) prescribing information. Fresenius Kabi USA, LLC.

10. U.S. Food and Drug Administration. (2022). FDA approves Udenyca Onbody for pegfilgrastim administration. https://www.fda.gov